Unlike in breast cancer, where Cyclin D1 influences neoadjuvant chemotherapy choices, pancreatic cancer lacks clinical trial data supporting Cyclin D1‐based treatment decisions. Here, CCND1 is linked to familial pancreatic carcinoma.